La española WerfenLife adquiere la estadounidense Accriva Diagnostics por $380M para reforzar su división de Diagnóstico in Vitro.

, , ,
Integral service around a transaction
BY : Diego Gutiérrez10/02/2017
WerfenLife, el gigante médico catalán  que factura €1.175M anuales quiere potenciar su división de diagnostico in vitro y para ello ha comprado Accriva Diagnostics y la alema Tem . Por otro parte, quiere ir reduciendo el peso de su división de dispositivos médicos y pretende vender Bolton Médica.
Análisis Corporate finance Werfenlife

WerfenLife, es un gigante médico que factura €1.175M anuales y que no ha para de crecer. La empresa tiene tres divisiones: diagnóstico in vitro y distribución de material médico y los dispositivos médicos. Aunque las tres divisiones crecen año tras año, La división de dispositivos médicos es la que menor peso tiene en las ventas  y WerfenLife ha decidido   especializar su grupo en las divisiones mayores, más escalables y rentables: las de diagnóstico in vitro y de distribución de material médico. Es por eso que se está deshaciendo de su división de dispositivos y está consiguiendo recursos para su división de diagnóstico.

El año pasado estuvieron planeando salir a bolsa, pero al final no salieron porque la empresa era rentable. Mientras WerfenLife tenga esta capacidad para generar fondos, los hermanos Rubiralta no piensan acudir al mercado de valores.

La española WerfenLife  adquiere la estadounidense Accriva Diagnostics por $380M para reforzar su división de Diagnóstico in Vitro.

Compra de Accriva Diagnostics por €358M

Accriva, con sede en San Diego, facturó 94 millones de dólares en 2016, y desarrolla, produce y distribuye pruebas diagnósticas para coagulación.

WerfenLife ha explicado que la cartera de productos de Accriva, que cuenta con 460 empleados, tiene un "alto encaje estratégico" en el negocio de Werfen, la división que aglutina el negocio de diagnóstico in vitro de WerfenLife.

Esta compra complementa la compra de la alemana Tem, también en el segmento de diagnóstico in vitro.

Compra de Tem  en 2016

En Octubre de 2016 Werfenlife compró Tem, por €125M.

Tem, que también opera en Estados Unidos, está especializada en desarrollo, producción y distribución de pruebas diagnósticas que ayudan a tomar mejores decisiones sobre la necesidad de realizar o no una transfusión de sangre y el uso de hemoderivados. La compañía tiene un volumen de negocio de unos €30M.

Otros post que te pueden interesar

Si estas buscando inversores, quieres comprar o vender una empresa, ponte en contacto con nosotros. Abra-Invest cuenta con un equipo experto en cada área a tu disposicón. Llama al +34 946424142 o rellena el formulario de contacto.

The M&A Professionals

Meet our services

MEET
OUR
metodologY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
"Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu